OrphAI Therapeutics key facts
- Developer of a precision therapeutics technology designed to treat cancer and rare diseases.
- OrphAI Therapeutics’s last known valuation is $300.0M.
- It has raised $154.5M; the latest was Later Stage VC ($56.5M) in Oct 2024.
- Notable investors include YuanBio Venture Capital, Yonghua Capital, 4Catalyzer, Albany Capital (Australia), Gravity Ventures (Korea) — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch OrphAI Therapeutics: the Monday email on marks, rounds and moves
OrphAI Therapeutics funding rounds
No funding rounds for OrphAI Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
OrphAI Therapeutics valuation
OrphAI Therapeutics's last known valuation is $300 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
OrphAI Therapeutics investors
7 investors are on record for OrphAI Therapeutics, including YuanBio Venture Capital, Yonghua Capital, 4Catalyzer and Albany Capital (Australia).
About OrphAI Therapeutics
Developer of a precision therapeutics technology designed to treat cancer and rare diseases. The company's technology accelerates drug development by deploying technologies including next-gen sequencing, genome editing, chemical genomics and combinational drug screening with deep learning to match clinical drugs, enabling doctors to treat diseases by providing significant therapeutic benefits for patients.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2013
- Employees
- 16
- Website
- orphai-therapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
OrphAI Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.